The use of gallium-68 labeled somatostatin receptors in PET/CT imaging

PET Clinics

Volumn 9, Issue 3, 2014, Pages 323-329

  Ambrosini, Valentina ^a   Nanni, Cristina ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

68Ga DOTA SSTRTs; Neuroendocrine tumors; PET CT; Somatostatin receptors

Indexed keywords

DOTA SOMATOSTATIN RECEPTOR GA 68; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; 68GA-DOTANOC; 68GA-DOTATATE; GA(III)-DOTATOC; GALLIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; SOMATOSTATIN RECEPTOR;

ADRENAL GLAND; CANCER STAGING; CATION EXCHANGE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFECT; HUMAN; HYPOPHYSIS; LIVER; NEUROENDOCRINE TUMOR; PANCREAS; PET-CT SCANNER; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; REVIEW; SENSITIVITY AND SPECIFICITY; SPLEEN; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; URINARY TRACT; ANALOGS AND DERIVATIVES; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION;

DIAGNOSIS, DIFFERENTIAL; GALLIUM RADIOISOTOPES; HUMANS; NEOPLASMS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84903712498     PISSN: 15568598     EISSN: 18799809     Source Type: Journal    
DOI: 10.1016/j.cpet.2014.03.008     Document Type: Review

References (26)

1. E.P. Krenning, D.J. Kwekkeboom, and W.H. Bakker et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 1993 716 731
2. J. Kowalski, M. Henze, and J. Schuhmacher et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors Mol Imaging Biol 5 2003 42 48
3. I. Buchmann, M. Henze, and S. Engelbrecht et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 34 10 2007 1617 1626
4. P. Antunes, M. Ginj, and H. Zhang et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34 7 2007 982 993
5. J.C. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr Rev 24 4 2003 389 427
6. J.C. Reubi, and B. Waser Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting Eur J Nucl Med Mol Imaging 30 5 2003 781 793
7. M. Gabriel, C. Decristoforo, and D. Kendler et al. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 4 2007 508 518
8. V. Ambrosini, D. Campana, and P. Tomassetti et al. 68Ga-labelled SSTRTs for diagnosis of gastroenteropancreatic NET Eur J Nucl Med Mol Imaging 39 Suppl 1 2012 S52 S60
9. I. Virgolini, V. Ambrosini, and J.B. Bomanji et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated SSTRTs: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE Eur J Nucl Med Mol Imaging 37 10 2010 2004 2010
10. T.D. Poeppel, I. Binse, and S. Petersenn et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors J Nucl Med 52 12 2011 1864 1870
11. L. Kabasakal, E. Demirci, and M. Ocak et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours Eur J Nucl Med Mol Imaging 39 8 2012 1271 1277
12. R. Srirajaskanthan, I. Kayani, and A.M. Quigley et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy J Nucl Med 51 6 2010 875 882
13. V. Ambrosini, D. Campana, and L. Bodei et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors J Nucl Med 51 5 2010 669 673
14. D. Campana, V. Ambrosini, and R. Pezzilli et al. Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors J Nucl Med 51 3 2010 353 359
15. D. Kaemmerer, L. Peter, and A. Lupp et al. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours Eur J Nucl Med Mol Imaging 38 9 2011 1659 1668
16. V. Prasad, V. Ambrosini, and M. Hommann et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT Eur J Nucl Med Mol Imaging 37 1 2010 67 77
17. V. Ambrosini, P. Tomassetti, and P. Castellucci et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours Eur J Nucl Med Mol Imaging 35 8 2008 1431 1438
18. A. Haug, C.J. Auernhammer, and B. Wängler et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 36 5 2009 765 770
19. K.P. Koopmans, O.N. Neels, and I.P. Kema et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results Crit Rev Oncol Hematol 71 3 2009 199 213
20. I. Velikyan, G.J. Beyer, and B. Långström Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity Bioconjug Chem 15 2004 554 560
21. G.J. Meyer, H. Maecke, and J. Schuhmacher et al. 68Ga-labelled DOTA-derivatised peptide ligands Eur J Nucl Med Mol Imaging 31 2004 1097 1104
22. K.P. Zhernosekov, D.V. Filosofov, and R.P. Baum et al. Processing of generator-produced 68Ga for medical application J Nucl Med 48 2007 1741 1748
23. W.A. Breeman, M. de Jong, and E. de Blois et al. Radiolabelling DOTA-SSTRTs with 68Ga Eur J Nucl Med Mol Imaging 32 2005 478 485
24. C. Decristoforo, R. Knopp, and E. von Guggenberg et al. A fully automated synthesis for the preparation of 68Ga-labelled SSTRTs Nucl Med Commun 28 2007 870 875
25. M.E. Mayerhoefer, M. Schuetz, and S. Magnaldi et al. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? Eur Radiol 22 4 2012 938 946
26. P. Castellucci, J. Pou Ucha, and C. Fuccio et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT J Nucl Med 52 6 2011 886 890